A real-world multicenter study to determine efficacy and safety of sofosbuvir/velpatasvir/Voxilaprevir among NS5A inhibitor-experienced HCV patients in Asia
Latest Information Update: 28 Dec 2022
At a glance
- Drugs Sofosbuvir/velpatasvir/voxilaprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
Most Recent Events
- 28 Dec 2022 New trial record
- 08 Nov 2022 Results presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases